Plain-English translation of NCT07460947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new, intensive one-day treatment for people with borderline personality disorder who are having suicidal thoughts. The treatment combines a medication called D-cycloserine with repeated sessions of transcranial magnetic stimulation (TMS)—a non-invasive procedure that uses magnetic pulses to stimulate the brain. Researchers want to see if this combination can reduce suicidal thoughts and improve symptoms of borderline personality disorder.
Borderline personality disorder can be very difficult to treat, and many people with this condition experience severe suicidal thoughts that don't always respond well to standard treatments. This trial is exploring whether a one-day intensive combination of the medication and brain stimulation might offer a faster, more effective option for people in crisis.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic for baseline interviews and testing, then complete weekly questionnaires for 4 weeks before your treatment day. On the evening before your treatment, you would take the medication. On the treatment day itself, you would receive up to 20 short magnetic stimulation sessions (each lasting about 3 minutes, spaced 30 minutes apart) in the clinic—this full day visit may last up to 12 hours. After that, you would complete weekly questionnaires for 6 weeks to track how you're doing.
AI-generated summary from trial data · Sep 5, 2026 · Not medical advice
United States